Another meta-analysis of 22 trials assessing the incidence of AF and atrial flutter (AFL) in patients with T2DM and HF, SGLT2 inhibitors led to an 18% reduction in AF/AFL occurrence compared to the placebo [192]. Here, SLC5A2 is linked to type 2 diabetes mellitus.